Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistimethate sodium plus carbapenems for carbapenem-resistant Gram-negative infections (China, single-arm)
ChiCTR2500114879Phase 4Completed
- Sponsor
- Tangdu Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of colistimethate sodium in Gram-negative bacterial infection, hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and 4 more, sponsored by Tangdu Hospital. Primary endpoint: Patient mortality rate. Started Dec 2025; status: completed.
02
Drugs
colistimethate sodium
03
Conditions
Gram-negative bacterial infectionhospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)bloodstream infection (BSI)
Beyond the preview
Go deeper on ChiCTR2500114879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114879.